Event Date/Time: May 17, 2012
End Date/Time: Jan 17, 2013
National experts in HCV management to meetâ€“live & onlineâ€“for a virtual education congress.
Choose from Four 1-hour interactive CME sessions.
Register now, thereâ€™s no cost to participate
Thursday, May 17, 2012, 11:00 AM â€“ 4:00 PM ET
Presented by the Johns Hopkins University School of Medicine
HCV Virtual Education Summit
Choose From Four 1-Hour Interactive CME Sessions.
Thursday, May 17, 2012
11:00 AM New Paradigms for the Treatment of Patients Infected with HCV Genotype 1: Peginterferon Alfa/Ribavirin Combined With HCV Protease Inhibitors
1:00 PM Maximizing Success and Minimizing Risks: The Role of IL28B Testing and Hepatitis C Viral Kinetic
2:00 PM Successful Office-Based Management of Patients With HCV Protease Inhibitors and Peginterferon/Ribavirin
3:00 PM The Treatment of Challenging HCV-Infected Patients
Sign up at www.IDCareLive.com thereâ€™s no cost to participate.
Each session has been approved for 1.0 AMA PRA Category 1 CreditTM.
Supported by educational grants from Abbott Laboratory Inc., Boehringer Ingelheim, Gilead Sciences and Merck & Co., Inc.
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENTS
The Johns Hopkins University School of Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Creditsâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Creditâ„¢ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Creditâ„¢ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Creditâ„¢ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 4 hours of credit for completing these programs.
DATE OF RELEASE/EXPIRATION
Live sessions will be available Thursday, May 17, 2012 from 11:00 AM- 4:00 PM ET
After participating in this activity, the participant will demonstrate the ability to:
ï‚Ÿ Identify patients who will most benefit from novel treatment options
ï‚Ÿ Describe the application of biomarkers to predict SVR in patients with HCV
ï‚Ÿ Revise office-based management of HCV by applying timely interventions and increasing therapy adherence
ï‚Ÿ Recognize special populations infected with HCV and successfully manage these challenging cases
ï‚Ÿ Evaluate the dynamics of HCV/HIV co-infection and apply proper treatment to avoid side effects and maximize SVR
Infectious disease specialists, gastroenterologists, hepatologists, primary care clinicians, and those clinicians affiliated with correctional facilities, Veteranâ€™s Administration hospitals, and alcohol/drug rehabilitation centers. A number of secondary audiences of healthcare providers such as nurses, physician assistants, and pharmacists may also be interested in participating in the program.
FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES
It is the policy of the Johns Hopkins University School of Medicine that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the course handout materials.